Business Description
BerGenBio ASA
ISIN : NO0013251173
Compare
Compare
Traded in other countries / regions
BGBIO.Norway7BG0.Germany0RU5.UKBGBIOO.SwedenBRRGF.USA IPO Date
2017-08-21Description
BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company's clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 478.75 | |||||
| Equity-to-Asset | 0.8 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -66.9 | |||||
| 3-Year EBITDA Growth Rate | 64.5 | |||||
| 3-Year EPS without NRI Growth Rate | 64.7 | |||||
| 3-Year FCF Growth Rate | 61.2 | |||||
| 3-Year Book Growth Rate | -80.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 21.54 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.06 | |||||
| 9-Day RSI | 31.47 | |||||
| 14-Day RSI | 35.06 | |||||
| 6-1 Month Momentum % | -44.85 | |||||
| 12-1 Month Momentum % | -41.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.05 | |||||
| Quick Ratio | 5.05 | |||||
| Cash Ratio | 4.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -198.5 | |||||
| Shareholder Yield % | -35.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -31124.18 | |||||
| Net Margin % | -29828.22 | |||||
| FCF Margin % | -32008.25 | |||||
| ROE % | -104.26 | |||||
| ROA % | -81.22 | |||||
| ROIC % | -728.93 | |||||
| ROC (Joel Greenblatt) % | -51504.22 | |||||
| ROCE % | -106.34 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 473.02 | |||||
| PB Ratio | 2.01 | |||||
| Price-to-Tangible-Book | 2.01 | |||||
| EV-to-EBIT | -1.48 | |||||
| EV-to-Forward-EBIT | -1.02 | |||||
| EV-to-EBITDA | -1.49 | |||||
| EV-to-Forward-EBITDA | -1.02 | |||||
| EV-to-Revenue | 450.05 | |||||
| EV-to-Forward-Revenue | 1543.51 | |||||
| EV-to-FCF | -1.63 | |||||
| Price-to-Net-Current-Asset-Value | 2.01 | |||||
| Price-to-Net-Cash | 2.24 | |||||
| Earnings Yield (Greenblatt) % | -67.73 | |||||
| FCF Yield % | -47.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BerGenBio ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.521 | ||
| EPS (TTM) (kr) | -4.939 | ||
| Beta | 1.77 | ||
| Volatility % | 139.5 | ||
| 14-Day RSI | 35.06 | ||
| 14-Day ATR (kr) | 0.266767 | ||
| 20-Day SMA (kr) | 9.8797 | ||
| 12-1 Month Momentum % | -41.5 | ||
| 52-Week Range (kr) | 8.799 - 34.6 | ||
| Shares Outstanding (Mil) | 39.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BerGenBio ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BerGenBio ASA Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
BerGenBio ASA Frequently Asked Questions
What is BerGenBio ASA(LTS:0RU5)'s stock price today?
The current price of LTS:0RU5 is kr8.95. The 52 week high of LTS:0RU5 is kr34.60 and 52 week low is kr8.80.
When is next earnings date of BerGenBio ASA(LTS:0RU5)?
The next earnings date of BerGenBio ASA(LTS:0RU5) is 2024-11-13.
Does BerGenBio ASA(LTS:0RU5) pay dividends? If so, how much?
BerGenBio ASA(LTS:0RU5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers